If you are seeing this, please disable your adblock software to view the full version of our annual report!

Bruce-Resized.jpg

Bruce Levine, PhD
ISCT President (2020 – 2022)
United States

An Inspiring and Resilient Community


In a year marked deeply by the ongoing COVID-19 pandemic, our professionals drive a concerted push that grows stronger than ever as many cell and gene therapies advance from discovery to development to commercialization.

2020 marked significant challenges, and yet, there is great opportunity ahead. We are at the cusp of a new wave in cell and gene therapies, and I know that this Society will be on the leading edge.

QueenieJang.jpg

Queenie Jang, BSc (Pharmacy), MBA,
Chief Executive Officer
Canada

Re-imagining the Community in an Unprecedented Year


2020 was an unprecedented year with unprecedented challenges for our Society. In response to the COVID-19 pandemic, ISCT rapidly repositioned to meet the changed needs of a global membership largely embedded in the fight on the frontlines. 

By taking action decisively and collaboratively, this Society proved that it has what it takes to lead the field in meeting emergent and systemic challenges. From the pivot from ISCT 2020 Paris to Paris Virtual, to the expanding scope of our collaborations across the sector, to the additions we have introduced to our committees and leadership rosters, ISCT has made extraordinary impacts in a year that was unrelenting in its challenges.

“In 2020, our society gained more than a thousand new members.”

It has been an important year for our mission. Alongside the challenges we have faced, cell and gene therapies have come to the forefront of public interest. As many of us know, the sector is forecasted to almost double in size within the next few years. Similarly, this community is growing at a rapid pace. 

ISCT Members, 2016 – 2020


While we could not connect in person, ISCT was able to come together to bring people and organizations, ideas and resources to address some of the key issues facing the sector today. This was no more apparent than during the ISCT 2020 Paris Virtual Annual Meeting.

With little more than eight weeks between public health decisions and our original meeting planned for a large scale in-person gathering in Paris, we devoted immense effort from our speakers, exhibitors, organizing committee, and head office, to pivot to a safe, virtual meeting model. We managed to develop and deliver a robust scientific program, key spotlight presentations honing on urgent topics, and a venue for emerging science to find fresh and interested eyes.

Along the way, we saw the community spirit that enrichens every ISCT Annual Meeting express itself in style. In the virtual environment, we wanted to deliver an experience that brought a sense of ‘coming home’, and of escaping, if only for a few hours, the day-to-day experience of the COVID-19 pandemic. We brought in avatars; speaker panels that were not just colleagues – but friends; networking, and as much of the in-person experience as we could translate to virtual.

We got to see great moments like the Paris Virtual Avatar Challenge (Thanks to Maroun Khoury). There were heartwarming social media posts of attendees embracing the Paris theme of our meeting, and finding fun alongside the hard work and innovation it takes to bring science to fruition.

We have grown stronger as a global community

In a year where many of our members fought on the frontlines of the COVID-19 pandemic, we saw an unprecedented increase in mentorship and giving back. Despite the pandemic’s impact on innovation – delaying clinical trials, disrupting supply chains, making in-person networking impossible – ISCT members found the means…

…to support one another, to endure, and to stay engaged during this year.

Our Board of Directors

The ISCT Board of Directors consists of:

  • President (Chair of the Board of Directors)
  • President-Elect
  • Immediate Past President (Chair of the Strategic Advisory Council)
  • Global Secretary
  • Global Treasurer
  • Regional Vice Presidents

  • Chief Scientific Officer
  • Chief Regulatory Officer
  • Chief Commercialization Officer
  • 4 Elected ISCT Members
  • Senior Editor of the Society’s Journal
  • Chief Executive Officer. 

The Board of Directors is the main administrative body which manages the governance and strategic oversight of the Society.

  • ISCT 2020-2021 Board of Directors
  • ISCT 2021-2022 Board of Directors

Chair

Bruce Levine, PhD
President
June 2020 – June 2022
Barbara and Edward Netter Professor in Cancer Gene Therapy
University of Pennsylvania
Philadelphia, PA, United States

Directors

Jacques Galipeau, MD
President-Elect
June 2020 – June 2022
University of Wisconsin-Madison
Madison, WI, United States 

John Rasko, AO, MBBS, PhD, FRCPA, FRACP, FAHMS
Chair, Strategic Advisory Council (Immediate Past President)
June 2020 – June 2022
Royal Prince Alfred Hospital
Sydney, Australia 

Lizette Caballero, BS, MT(ASCP)
Global Secretary
June 2019 – June 2022
UCSF Blood and Marrow Transplant Lab
San Francisco, CA, United States

Emily Hopewell, PhD
Global Treasurer
June 2020 – June 2023
Indiana University School of Medicine
Zionsville, Indiana

Bryan Choi, PhD
Asia, Regional Vice-President 
June 2021 – June 2023
Strategic Center For Regenerative Medicine (SCRM)
Inha University
Incheon, Korea

Rajiv Khanna, PhD AO
Australia & New Zealand, Regional Vice-President
June 2020 – June 2022
QIMR Berghofer Medical Research Institute
Brisbane, Australia

Massimiliano Gnecchi, MD, PhD
Europe, Regional Vice-President 
June 2021 – June 2023
University Of Pavia & IRCCS Policlinico San Matteo Hospital
Pavia, Italy

Mitchell Cairo, MD
North America, Regional Vice-President
June 2020 – June 2022
New York Medical College
New York, NY, United States

Antonio Carlos Campos de Carvalho, MD, PhD
South and Central America, Regional Vice-President
June 2021 – June 2023
Institute Of Biophysics
Federal University Of Rio De Janeiro
Rio De Janeiro, Brazil

Daniel J. Weiss, MD, PhD
Chief Scientific Officer

June 2016 – June 2022
University of Vermont
Burlington, VT, United States

Anthony Ting, PhD
Chief Commercialization Officer 
May 2020 – May 2022
Athersys
Cleveland, OH, United States

Karen Nichols, Esq.
Chief Regulatory Officer
March 2016 – June 2021
Vertex Pharmaceuticals
Cambridge, MA, United States

Dominique Farge, MD, PhD
Elected Member MD
June 2021 – June 2023
Greater Paris University Hospitals – AP-HP
Paris, France

Sowmya Viswanathan, PhD
Elected Member PhD
June 2020 – June 2022
University Health Network and University of Toronto
Canada

Vicki Antonenas, BSc, MSc
Elected Member Technologist
June 2020 – June 2022
Sydney Cellular Therapies Laboratory,
Westmead Hospital
Australia

Diane Kadidlo, BSc, MT(ASCP), SBB
Elected Member Technologist
June 2021 – June 2021
Molecular And Cellular Therapeutics
University Of Minnesota
St Paul, Minnesota, United States

Donald Phinney, PhD
Senior Editor of the Journal 
October 2018 – Present
Professor at The Scripps Research Institute
Jupiter, FL, United States

Queenie Jang, BSc (Pharmacy), MBA
Chief Executive Officer 
ISCT
Vancouver, BC, Canada

Chair

Bruce Levine, PhD
President
June 2020 – June 2022
Barbara and Edward Netter Professor in Cancer Gene Therapy
University of Pennsylvania
Philadelphia, PA, United States

Directors

Jacques Galipeau, MD
President-Elect
June 2020 – June 2022
University of Wisconsin-Madison
Madison, WI, United States 

John Rasko, AO, MBBS, PhD, FRCPA, FRACP, FAHMS
Chair, Strategic Advisory Council (Immediate Past President)
June 2020 – June 2022
Royal Prince Alfred Hospital
Sydney, Australia 

Lizette Caballero, BS, MT(ASCP)
Global Secretary
June 2019 – June 2022
UCSF Blood and Marrow Transplant Lab
San Francisco, CA, United States

Emily Hopewell, PhD
Global Treasurer
June 2020 – June 2023
Indiana University School of Medicine
Zionsville, Indiana

Oscar Lee, MD, PhD
Asia, Regional Vice-President 
June 2019 – June 2021
National Yang- Ming University
Taiwan

Rajiv Khanna, PhD AO
Australia & New Zealand, Regional Vice-President
June 2020 – June 2022
QIMR Berghofer Medical Research Institute
Brisbane, Australia

Joan Garcia-Lopez, MD, PhD
Europe, Regional Vice-President 
June 2019 – June 2021
Director of Research and Education Banc de Sang i Teixits Barcelona, Spain

Mitchell Cairo, MD
North America, Regional Vice-President
June 2020 – June 2022
New York Medical College
New York, NY, United States

Patricia Rocco, MD, PhD
South and Central America, Regional Vice-President
June 2019 – June 2021
Federal University of Rio de Janeiro
Rio de Janeiro, Brazil

Daniel J. Weiss, MD, PhD
Chief Scientific Officer

June 2016 – June 2022
University of Vermont
Burlington, VT, United States

Anthony Ting, PhD
Chief Commercialization Officer 
May 2020 – May 2022
Athersys
Cleveland, OH, United States

Karen Nichols, Esq.
Chief Regulatory Officer
March 2016 – June 2021
Vertex Pharmaceuticals
Cambridge, MA, United States

Elizabeth Stenger, MD, MSc
Elected Member MD
June 2019 – June 2021
UPMC Children’s Hospital of Pittsburgh 
Pittsburgh, PA, United States

Sowmya Viswanathan, PhD
Elected Member PhD
June 2020 – June 2022
University Health Network and University of Toronto
Canada

Vicki Antonenas, BSc, MSc
Elected Member Technologist
June 2020 – June 2022
Sydney Cellular Therapies Laboratory,
Westmead Hospital
Australia

Anne Lamontagne, MSc 
Elected Member Technologist
June 2019 – June 2021
Clinical Cell and Vaccine Production Facility
University of Pennsylvania
Philadelphia, PA, United States 

Donald Phinney, PhD
Senior Editor of the Journal 
October 2018 – Present
Professor at The Scripps Research Institute
Jupiter, FL, United States

Queenie Jang, BSc (Pharmacy), MBA
Chief Executive Officer 
ISCT
Vancouver, BC, Canada

The ISCT Response to COVID-19

Pivoting to meet the Pandemic

The COVID-19 Pandemic raised significant challenges across the globe, and the cell and gene therapy sector was not immune. To meet the needs of our members in turbulent times, ISCT made several strategic pivots in 2020, emphasizing community, spotlighting discussions advancing COVID-19 treatments using cell and gene applications, and going virtual with the ISCT 2020 Annual Meeting.

Despite all of the challenges presented, ISCT membership grew to record numbers, emphasizing the need for community, connection and a common purpose. Despite the public health and economic impacts of the ongoing pandemic, ISCT continues to take the steps needed to bring cell and gene therapy stakeholders together to chart the path forward. 

ISCT 2020 Chief Scientific Officer Spotlight on COVID-19

As part of the Society response to COVID-19, ISCT Chief Scientific Officer (CSO) Daniel J. Weiss led two sessions bookending the ISCT 2020 Paris Virtual Annual Meeting. This timely and critical pair of sessions provided key discussion examining the state of therapeutic efforts to address COVID-19, as well as the potential responses that could be leveraged by cell and gene therapy stakeholders. 

Part I. “The Force Awakens”
This session focused on pathogenesis and on the experiences of health care workers on the front lines in Italy, New York City, and China. ISCT members shared their experiences at the forefront of both clinical care and mechanistic investigations, and the panel discussed the impact of travel and shipping restrictions on clinical cell therapy programs.

Part II. “A New Hope”
This session focused on novel cell-based and immunologic-based therapeutics. Facing an ongoing threat of emerging infectious disease, the panel considered what role cell therapies can play therapeutically and how studies should be conducted and interpreted. Through translational and clinical science, cell and gene therapies were discussed as a new hope for the development of novel therapeutics.

ISCT Showcase on COVID-19 Research 

The COVID-19 pandemic put a spotlight on the possibilities that are already emerging in cell and gene therapy research. Through scientific presentations and the creation of a research spotlight, including several scientific review papers authored by ISCT members, ISCT has played a part in consolidating the scientific knowledge available on proven applications supported by research. 

Simultaneously, through the actions of several key members and of the ISCT Presidential Task Force on Unproven/Unethical Cell and Gene Therapies (PTF), ISCT has played a key role in maintaining integrity, at a time when it is most needed, across many interactions between legitimate sector stakeholders and the public

Cell-based treatments for COVID-19
By Laertis Ikonomou, PhD

The COVID-19 pandemic has produced a rush of candidate treatments, currently evaluated worldwide for safety and efficacy. We discuss issues related to the development of cell-based interventions for COVID-19.

Current Status of Cell-Based Therapies for Respiratory Virus Infections: Applicability to COVID-19
By Maroun Khoury, Jimena Cuenca, Fernanda F. Cruz, Fernando E. Figueroa, Patricia R. M. Rocco, Daniel J. Weiss



Published in the European Respiratory Journal

Cell-Based Therapies for COVID-19: Proper Clinical Investigations are Essential
By Maroun Khoury, Patricia R.M. Rocco, Mauro Krampera, Ivan Martin, Sowmya Viswanathan, Donald G Phinney, Jan A. Nolta, Katarina LeBlanc, Jacques Galipeau and Daniel J. Weiss

Published in Cytotherapy

ISCT takes a stand against organizations marketing unproven COVID-19 cell and gene therapies
Wednesday, March 25, 2020

Following up on a statement made on March 20th, ISCT has issued a press release taking a stand against organizations marketing unproven COVID-19 cell and gene therapies.

ISCT 2020 Paris Virtual
ISCT CSO Global Showcase on COVID-19
Part I: “The Force Awakens”

  • Review of Current Understanding of COVID-19 Pathogenesis
  • Reports from the Front Lines
  • Supply Chain Issues

LIVE at ISCT 2020 Paris Virtual
ISCT CSO Global Showcase on COVID-19 
Part II: “A New Hope”

  • MSC-based Approaches
  • Immuno-Gene Therapy Approaches

Warnings on stem cells touted as COVID therapy
An Interview with ISCT Presidential Task Force Members Laertis Ikonomou, Daniel J. Weiss, and Megan Munsie by The Medical Republic regarding concerns about the marketing of unproven therapies during the pandemic.

ISCT CSO Daniel J. Weiss moderates Webinar on Potential COVID-19 Treatments Using Cell Therapies
Hosted by ARM, ARMF, and ISCT

Preying on Public Fears and Anxieties in a Pandemic: Businesses Selling Unproven and Unlicensed “Stem Cell Treatments” for COVID-19
By Leigh Turner, PhD

#ISCTTogether

Recognizing the need for community and connection, the ISCT community came together virtually to connect beyond the science to maintain resilience, develop hope, and work together in the face of the COVID-19 pandemic.

#ISCTTogether is a campaign of connection, envisioned by ISCT President Bruce Levine, to support one another through the critical challenges that continue to emerge as a result of the pandemic. 

Showcasing stories of members adapting to new circumstances, learning to work together in a new normal, and developing connections that go beyond the science, #ISCTTogether speaks to the heart of the Society – inclusive collaboration in a truly global setting. 

April 2020 – ISCT ANZ Regional Secretary Vicki Antonenas processes her last expected shipment of fresh Haematopoietic Progenitor Cells at Sydney International Airport

Pivoting to Virtual

For ISCT, the most visible and tangible impact of the pandemic was the difficult but necessary decision to pivot from the planned ISCT 2020 Annual Meeting in Paris, France, to a Virtual Meeting, with Paris recreated in the home offices and living rooms of ISCT members around the world.

While there were numerous challenges in pioneering a virtual event with less than 8 weeks to plan, the ISCT community came together and embraced the concept wholeheartedly. With over 2000 attendees, ISCT 2020 Paris Virtual broke new ground in encouraging truly global participation. 

 

Living the Paris theme, the Organizing Committee worked to bring attendees together, recognizing that annual meetings serve not only as connective points for scientific collaboration, but also for an engaged community. 

Presenters and attendees alike took the initiative several steps further, theming personal backdrops, bringing in Paris cheer, and most of all, having a moment of respite and good vibes that stood out among the days of a still-ongoing pandemic. 

Embodying the spirit of ISCT fun, delegates took it upon themselves to insert their own photos into the ISCT 2020 Paris Virtual environment; the ISCT 2020 Paris Virtual Avatar Challenge was born! 

PIVOTING TO MEET THE PANDEMIC

Building Global Consensus in Cell and Gene Therapy

Moving the Field Forward

ISCT engages in unique collaboration between academia, regulatory bodies and industry partners in cell and gene therapy translation with a growing reputation as the community where these diverse partners can come together under the common mission of advancing CGT to improve patients’ lives. ISCT continues to build public trust and integrity for the field as a whole, as a powerful and visible voice for sector stakeholders.  

In 2019, Google released an updated advertising policy, prohibiting advertisements for unproven or experimental medical techniques such as most stem cell therapy, cellular (non-stem) therapy and gene therapy, meant to limit the reach of bad actors that offer unproven, unlicensed and potentially harmful cell and gene based interventions. This  action was lauded by many in the field, including ISCT, as a stand against unproven and unethical treatments. 

Spearheaded by the ISCT Presidential Task Force on the Use of Unproven and/or Unethical Cell and Gene Therapies (PTF), ISCT brought together over 20 stakeholder organizations to consult with Google on  unintended negative consequences on scientifically legitimate therapeutic uses of stem cells.

These supporting organizations represent an important collaborative effort to ensure high standards and public trust in advancing the development of cell and gene therapies, as proven products and ongoing clinical research become more prominent and require more direct public outreach.

CGT Standards and Harmonization

iso-logo.png
usp-logo.jpg
iccbba-logo.jpeg

ISCT is composed of stakeholders and leaders across a translational spectrum, creating opportunities for productive collaborations that can lead to sector harmonization and standards that are accepted across commercial, academic, and regulatory domains. 

ISCT contributed to consultations for several key agencies across the globe, including the International Standards Organization (ISO), where the ISCT Mesenchymal Stromal Cell Committee provided expert opinions on developing MSC definitions and standards; United States Pharmacopeia (USP), with which ISCT participates in developing new CGT relevant monographs; and the International Council for Commonality in Blood Banking Automation (ICCBBA),  to standardize cell type/source abbreviations commonly used in ISBT 128 labeling standards.

ISCT is a community that connects the dots when it comes to developing the standards and harmonization needed to efficiently and effectively move the field forward. 

FDA Cell Therapy Liaison Meeting (CTLM) 2020

ISCT continues to host an annual liaison meeting between key CGT sector stakeholders and the FDA Center for Biologics Evaluation and Research (CBER). Continuing to adapt to a changing world and re-imagining our programs, the 2020 CTLM was  adapted to a virtual format, enabling expansion to the agenda and opening new possibilities for future meetings.

The 2020 CTLM addressed several critical topics including:

  • Donor safety and standards
  • Long-term tracing of cell therapy recipients
  • Regulatory pathways for approved genetically modified products
  • CMC comparability of CGT
  • Framework for use of research grade materials in manufacturing of cellular therapies
Moving the field forward

Cytotherapy®

New URL. New Pipelines. Same Excellence.
//isct-cytotherapy.org 

Cytotherapy®, the Official Journal of ISCT, publishes novel and innovative results from high quality scientific and clinical research in the fields of cell and gene therapy. ISCT continues to advance the field, and so the journal must advance as well. This is the journey of Cytotherapy building further upon its already significant roots, to create a consistent impact on the advancement of Cell and Gene therapies. 

2020 marked significant shifts in the outreach and engagement of Cytotherapy. Building on the engagement of our scientific community within our annual meetings and in committees, the Journal continues to expand on its status as a visible and effective publication in the field where rigorous and exciting scientific advancement is discussed.

 

Our Editorial Leadership Team

“Patrick brings tremendous enthusiasm to the role of Commissioning Editor, which adds great energy to an already outstanding team of Editors. This enthusiasm has already translated into several exciting new initiatives at Cytotherapy, which I am confident will continue the journal’s rapid growth.”

Don Phinney, PhD
Senior Editor
United States

Patrick Hanley, PhD
Commissioning Editor
United States

“A key challenge is authenticity. We are all overwhelmed with emails every morning – ‘Dear Dr. Honorable Professor Hanley J Patrick, PhD, a fair greeting for the day. We invite you to publish a journal in the annals of unicorn surgery…’ It will be a challenge for us to eclipse the predatory journals and invite authors to contribute worthwhile content – but this is something we can achieve, by leveraging our extensive network and adding a personalized touch.”

(Hover or tap to remove the underlay)

A Warm Welcome to our New Editors

ISCT is pleased to welcome new Commissioning Editor for Cytotherapy, Dr. Patrick Hanley.

Within this role, Dr. Patrick Hanley joins the editorial board to develop the Journal’s selection of scientific publications, while liaising with key leaders in the field to develop focused and cutting-edge discourse. In this role, Dr. Hanley will help to identify areas of growth for the Journal to target, and set the groundwork for contributing authors and editorial board members to coordinate on emerging publications. He begins his role with the aim of expanding outreach to target a special issue of Cytotherapy for each year, in addition to an expansion of review and research articles. 

Alongside this, Dr. Hanley will implement his vision on Journal development strategies in close partnership with Dr. Donald Phinney, Senior Editor of Cytotherapy, to steward the continued growth of the Journal going forward. 

“I’d like to include Early Stage Professionals (ESPs) as much as possible. I think they (we?) are full of ideas, creativity, and enthusiasm. With proper mentorship they will be an invaluable resource for ISCT that will pay dividends now, but especially in the future…” 

“…A part of that will be leaning on the scientific committees to include ESPs as appropriate and working with them to develop reviews, white papers, and special editions that are of interest to the community. “

Interested in learning more about what Dr. Hanley has envisioned?

Leadership Transitions, Additions, Movements:

Description

Inaugural Insta-Your-Cells Photo Challenge

The 2020-2021 Insta-Your-Cells photo challenge engaged the cell therapy community and showcased some of the fascinating imagery that can emerge from laboratory work. This year, over 50 images were submitted to compete for a featured spotlight on the front cover of Cytotherapy, and images garnering the most votes from ISCT members earned prizes from a pool including registration to ISCT 2021 New Orleans VIRTUAL.

Click the toggle below to see the images that were selected to be featured on the front cover of Cytotherapy in 2021

Making an Impact

In 2020, Cytotherapy maintained a strong impact factor of 4.218, with a 43% increase in submissions, optimized editorial speeds, and strong quality control. A new focus within the scope of the Journal has been establishing a bank of open access content for key papers that are of critical interest to sector stakeholders. Open access publications now account for over 15% of Cytotherapy content.

The push towards becoming a more accessible publication has also driven the Editorial Board to provide a fresh and updated website, with new pipelines to publication connected to the ISCT Annual Meetings and other scientific events.

Talking with Giants: The 2021 ISCT Major Award Recipients

Description

New URL. New pipelines. Same excellence.

Our Three Pillars

ISCT Committees represent an invaluable network of dedicated scientific leaders that work to develop and deliver papers that advance the field of cell and gene therapy. Below are a featured series of their publications throughout this year. 

For more information on contributing to one of our committees, take a look at our Committee Directory.

The ISCT scientific community operates on a global scale, providing expert review and support in the interest of proven and safe research practices.

Through liaison work with standards organizations, a broader scientific community, and with investigatory stakeholders, ISCT conducts thought leadership in the field of cell and gene therapy on a global scale. Below is a snapshot of some actions taken by ISCT committees over the past year:

International Council for Commonality in Blood Banking Automation
1. Joint publication with the MSC Committee
International Standards Organization*
2. Standards for hBM-MSC Banking
3.  Standards for hUC-MSC Banking

*ISCT has provided ongoing liaison work for two biobanking standards documents, providing consultation around nomenclature for the international standards organization

International Society for Extracellular Vesicles
4. Consultation from the ISCT Presidential Task Force on Unproven/Unethical Cell & Gene Therapies
World Health Organization (WHO)
5.  ISCT and the International Nonproprietary Names (INN) Programme have been collaborating on cell and gene therapy standardization efforts of the WHO
0

Consultations with International Organizations

Since 2004, ISCT has been the host coordinating over 15 stakeholder organizations in the annual FDA Cell Therapy Liaison Meeting (CTLM). These closed meetings enable the cell and gene therapy community to inform the FDA of specific concerns, challenges and recent developments to advance the regulatory field. 

Each year, the CTLM report provides valuable coverage of key topics for regulatory consideration, summarizing the presentations that took place at the meeting, and providing key takeaways that are particularly useful to sector stakeholders. 

ISCT offers regulatory review and consultation from cell and gene therapy experts for regulatory authorities worldwide.

Review and recommendations are made by our global task force, as well as by regional Legal and Regulatory Affairs Committees in our North America, Europe, and Australia and New Zealand regions. Each consultation consists of significant comments, suggested revisions, and edits for regulatory documentation. Below are the major guidance reviews in 2020:

Australian Parliament
3. Comments on the TGA review of TGO88
4. Response to Parliamentary Inquiry on Approval Processes

0

Regulatory Consultations and Supports

Spearheaded by the ISCT Business Models & Investment Subcommittee, the ISCT Investigators to Investors (I to I) program was created in 2018 with a goal to bridge the knowledge gap between investigators and investors within the cell and gene therapy (CGT) sector. The program strives to educate investigators on how to successfully attract investor attention and capital, as well as support investors in conducting diligence and understanding opportunities within the CGT industry. Ultimately, the I to I program engages these two stakeholder groups in critical conversations that advance the development and delivery of cell and gene therapies.

In 2020, the I to I program published a key paper following up on the results of an investment stakeholder survey in the cell and gene therapy industry, conducted in partnership with Bloomberg. This paper, published on an open access basis, provides significant insights into the challenges facing companies in the sector seeking to engage investors, while forecasting trends for capital investment in CGT on a comparative basis to biopharmaceutical investments.

The I to I program has also been the driving force behind the ongoing Partnering in Japan series of webinars, developing and sponsoring a webinar in December 2020, focusing on the key lessons learned by leaders in Cell and Gene Therapy in the wake of the Japanese PMDA Conditional Approvals Act.

Membership: 50% outside of the United States from 60+ countries

Co-Founded Organizations

Strategic Liaisons

AABB-Logo.png
ASTCT-Logo-1.png
ARM-logo.png
AHCTA-Logo.png
ARMF-Logo.png
BAA-Logo.png
CARM-Logo.png
Catapult.png
logo-cellCAN-en.png
yukSxZ2M_400x400.jpg
EATRIS-logo.png
FIRM-Logo.png
ICCBBA-Logo.png